Pathogenic germline variants in patients with endometrial cancer of diverse ancestry.

ancestry disparities endometrial cancer genetic testing germline finding race

Journal

Cancer

ISSN: 1097-0142

Titre abrégé: Cancer

Pays: United States

ID NLM: 0374236

Informations de publication

Date de publication:
27 Oct 2023

Historique:

revised: 04 08 2023

received: 30 06 2023

accepted: 10 08 2023

medline: 27 10 2023

pubmed: 27 10 2023

entrez: 27 10 2023

Statut: aheadofprint

Résumé

Racial disparities in outcomes exist in endometrial cancer (EC). The contribution of ancestry-based variations in germline pathogenic variants (gPVs) is unknown. Germline assessment of ≥76 cancer predisposition genes was performed in patients with EC undergoing tumor-normal Memorial Sloan Kettering Cancer Center Integrated Mutation Profiling of Actionable Cancer Targets sequencing from January 1, 2015 through June 30, 2021. Self-reported race/ethnicity and Ashkenazi Jewish ancestry data classified patients into groups. Genetic ancestry was inferred from Memorial Sloan Kettering Cancer Center Integrated Mutation Profiling of Actionable Cancer Targets. Rates of gPV and genetic counseling were compared by ancestry. Among 1625 patients with EC, 216 (13%) had gPVs; 15 had >1 gPV. Rates of gPV varied by self-reported ancestry (Ashkenazi Jewish, 40/202 [20%]; Asian, 15/124 [12%]; Black/African American (AA), 12/171 [7.0%]; Hispanic, 15/124 [12%]; non-Hispanic (NH) White, 129/927 [14%]; missing, 5/77 [6.5%]; p = .009], with similar findings by genetic ancestry (p < .001). We observed a lower likelihood of gPVs in patients of Black/AA (odds ratio [OR], 0.44; 95% CI, 0.22-0.81) and African (AFR) ancestry (OR, 0.42; 95% CI, 0.18-0.85) and a higher likelihood in patients of Ashkenazi Jewish genetic ancestry (OR, 1.62; 95% CI; 1.11-2.34) compared with patients of non-Hispanic White/European ancestry, even after adjustment for age and molecular subtype. Somatic landscape influenced gPVs with lower rates of microsatellite instability-high tumors in patients of Black/AA and AFR ancestry. Among those with newly identified gPVs (n = 114), 102 (89%) were seen for genetic counseling, with lowest rates among Black/AA (75%) and AFR patients (67%). In those with EC, gPV and genetic counseling varied by ancestry, with lowest rates among Black/AA and AFR patients, potentially contributing to disparities in outcomes given implications for treatment and cancer prevention. Black women with endometrial cancer do worse than White women, and there are many reasons for this disparity. Certain genetic changes from birth (mutations) can increase the risk of cancer, and it is unknown if rates of these changes are different between different ancestry groups. Genetic mutations in 1625 diverse women with endometrial cancer were studied and the lowest rates of mutations and genetic counseling were found in Black and African ancestry women. This could affect their treatment options as well as their families and may make disparities worse.

Sections du résumé

BACKGROUND BACKGROUND

Racial disparities in outcomes exist in endometrial cancer (EC). The contribution of ancestry-based variations in germline pathogenic variants (gPVs) is unknown.

METHODS METHODS

Germline assessment of ≥76 cancer predisposition genes was performed in patients with EC undergoing tumor-normal Memorial Sloan Kettering Cancer Center Integrated Mutation Profiling of Actionable Cancer Targets sequencing from January 1, 2015 through June 30, 2021. Self-reported race/ethnicity and Ashkenazi Jewish ancestry data classified patients into groups. Genetic ancestry was inferred from Memorial Sloan Kettering Cancer Center Integrated Mutation Profiling of Actionable Cancer Targets. Rates of gPV and genetic counseling were compared by ancestry.

RESULTS RESULTS

Among 1625 patients with EC, 216 (13%) had gPVs; 15 had >1 gPV. Rates of gPV varied by self-reported ancestry (Ashkenazi Jewish, 40/202 [20%]; Asian, 15/124 [12%]; Black/African American (AA), 12/171 [7.0%]; Hispanic, 15/124 [12%]; non-Hispanic (NH) White, 129/927 [14%]; missing, 5/77 [6.5%]; p = .009], with similar findings by genetic ancestry (p < .001). We observed a lower likelihood of gPVs in patients of Black/AA (odds ratio [OR], 0.44; 95% CI, 0.22-0.81) and African (AFR) ancestry (OR, 0.42; 95% CI, 0.18-0.85) and a higher likelihood in patients of Ashkenazi Jewish genetic ancestry (OR, 1.62; 95% CI; 1.11-2.34) compared with patients of non-Hispanic White/European ancestry, even after adjustment for age and molecular subtype. Somatic landscape influenced gPVs with lower rates of microsatellite instability-high tumors in patients of Black/AA and AFR ancestry. Among those with newly identified gPVs (n = 114), 102 (89%) were seen for genetic counseling, with lowest rates among Black/AA (75%) and AFR patients (67%).

CONCLUSIONS CONCLUSIONS

In those with EC, gPV and genetic counseling varied by ancestry, with lowest rates among Black/AA and AFR patients, potentially contributing to disparities in outcomes given implications for treatment and cancer prevention.

PLAIN LANGUAGE SUMMARY CONCLUSIONS

Black women with endometrial cancer do worse than White women, and there are many reasons for this disparity. Certain genetic changes from birth (mutations) can increase the risk of cancer, and it is unknown if rates of these changes are different between different ancestry groups. Genetic mutations in 1625 diverse women with endometrial cancer were studied and the lowest rates of mutations and genetic counseling were found in Black and African ancestry women. This could affect their treatment options as well as their families and may make disparities worse.

Identifiants

DOI: 10.1002/cncr.35071 PMID: 37886874

pubmed: 37886874

doi: 10.1002/cncr.35071

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Subventions

Organisme : NCI NIH HHS

ID : P30 CA008748

Pays : United States

Organisme : NIH HHS

ID : P30 CA008748

Pays : United States

Informations de copyright

Références

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA A Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763

Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110(4):354-361. doi:10.1093/jnci/djx214

Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. doi:10.1038/nature12113

Cote ML, Ruterbusch JJ, Olson SH, Lu K, Ali-Fehmi R. The growing burden of endometrial cancer: a major racial disparity affecting Black women. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2015;24(9):1407-1415. doi:10.1158/1055-9965.Epi-15-0316

Gaber C, Meza R, Ruterbusch JJ, Cote ML. Endometrial cancer trends by race and histology in the USA: projecting the number of new cases from 2015 to 2040. J Racial Ethn Health Disparities. 2016;4(5):895-903. doi:10.1007/s40615-016-0292-2

Collins Y, Holcomb K, Chapman-Davis E, Khabele D, Farley JH. Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. Gynecol Oncol. 2014;133(2):353-361. doi:10.1016/j.ygyno.2013.12.039

Pinheiro PS, Medina HN, Koru-Sengul T, et al. Endometrial cancer type 2 Incidence and survival disparities within subsets of the US Black population. Front Oncol. 2021;11:699577. doi:10.3389/fonc.2021.699577

Stadler ZK, Robson ME. Inherited predisposition to endometrial cancer: moving beyond Lynch syndrome. Cancer. 2015;121(5):644-647. doi:10.1002/cncr.29107

Gordhandas S, Rios-Doria E, Cadoo KA, et al. Comprehensive Analysis of Germline Drivers in Endometrial Cancer. J Natl Cancer Inst. 2023;115(5):560-569. doi:10.1093/jnci/djad016

Heald B, Mokhtary S, Nielsen SM, et al. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer. Gynecol Oncol. 2022;166(2):344-350. doi:10.1016/j.ygyno.2022.05.023

Karpel HC, Chern JY, Smith JM, Smith AJ, Pothuri B. Utility of germline multi-gene panel testing in patients with endometrial cancer. Gynecol Oncol. 2022;165(3):546-551. doi:10.1016/j.ygyno.2022.04.003

Levine MD, Pearlman R, Hampel H, et al. Up-front multigene panel testing for cancer susceptibility in patients with newly diagnosed endometrial cancer: a multicenter prospective study. JCO Precis Oncol. 2021;5:1588-1602. doi:10.1200/po.21.00249

Crosbie EJ, Ryan NAJ, Arends MJ, et al. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genet Med. 2019;21(10):2390-2400. doi:10.1038/s41436-019-0489-y

Dominguez-Valentin M, Sampson JR, Seppala TT, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2020;22(1):15-25. doi:10.1038/s41436-019-0596-9

Pennington KP, Walsh T, Lee M, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer. 2013;119(2):332-338. doi:10.1002/cncr.27720

Ring KL, Bruegl AS, Allen BA, et al. Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. Mod Pathol. 2016;29(11):1381-1389. doi:10.1038/modpathol.2016.135

de Jonge MM, de Kroon CD, Jenner DJ, et al. Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations: multicenter cohort study. J Natl Cancer Inst. 2021. doi:10.1093/jnci/djab036

Shu CA, Pike MC, Jotwani AR, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016;2(11):1434-1440. doi:10.1001/jamaoncol.2016.1820

Chapman-Davis E, Zhou ZN, Fields JC, et al. Racial and ethnic disparities in genetic testing at a Hereditary Breast and Ovarian Cancer Center. J Gen Intern Med. 2021;36(1):35-42. doi:10.1007/s11606-020-06064-x

Forman AD, Hall MJ. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer. Breast J. 2009;15((Suppl 1)):S56-S62. doi:10.1111/j.1524-4741.2009.00798.x

Reid S, Cadiz S, Pal T. Disparities in genetic testing and care among Black women with hereditary breast cancer. Curr Breast Cancer Rep. 2020;12(3):125-131. doi:10.1007/s12609-020-00364-1

Piedimonte S, Power J, Foulkes WD, et al. BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral. Int J Gynecol Cancer: Official Journal of the International Gynecological Cancer Society. 2020;30(11):1757-1761. doi:10.1136/ijgc-2020-001261

Czekalski MA, Huziak RC, Durst AL, Taylor S, Mai PL. Mainstreaming genetic testing for epithelial ovarian cancer by oncology providers: a survey of current practice. JCO Precis Oncol. 2022;6:e2100409. doi:10.1200/po.21.00409

Liu YL, Maio A, Kemel Y, et al. Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variants. Cancer. 2022;128(21):3870-3879. doi:10.1002/cncr.34434

Hinchcliff EM, Bednar EM, Lu KH, Rauh-Hain JA. Disparities in gynecologic cancer genetics evaluation. Gynecologic oncology. 2019;153(1):184-191. doi:10.1016/j.ygyno.2019.01.024

Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017-06-01 2017;23(6):703-713. doi:10.1038/nm.4333

Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). J Mol Diagn. 2015;17(3):251-264. doi:10.1016/j.jmoldx.2014.12.006

Cheng DT, Prasad M, Chekaluk Y, et al. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Med Genom. 2017;10(1):33. doi:10.1186/s12920-017-0271-4

Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424. doi:10.1038/gim.2015.30

Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372(23):2243-2257. doi:10.1056/NEJMsr1501341

Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318(9):825-835. doi:10.1001/jama.2017.11137

Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016;13(9):581-588. doi:10.1038/nrclinonc.2016.90

Momeni-Boroujeni A, Dahoud W, Vanderbilt CM, et al. Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas. Clin Cancer Res. 2021;27(9):2613-2623. doi:10.1158/1078-0432.Ccr-20-4436

Momeni-Boroujeni A, Nguyen B, Vanderbilt CM, et al. Genomic landscape of endometrial carcinomas of no specific molecular profile. Mod Pathol. 2022;35(9):1-1278. doi:10.1038/s41379-022-01066-y

Niu B, Ye K, Zhang Q, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics. 2014;30(7):1015-1016. doi:10.1093/bioinformatics/btt755

Rios-Doria E, Momeni-Boroujeni A, Friedman CF, et al. Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma. Gynecol Oncol. 2023;174:262-272. doi:10.1016/j.ygyno.2023.05.059. Epub 2023 May 26. PMID: 37245486.

Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44(16):e131. doi:10.1093/nar/gkw520

Arora K, Tran TN, Kemel Y, et al. Genetic ancestry correlates with somatic differences in a real-world clinical cancer sequencing cohort. Cancer Discov. 2022;12(11):2552-2565. doi:10.1158/2159-8290.Cd-22-0312

Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated individuals. Genome Res. 2009;19(9):1655-1664. doi:10.1101/gr.094052.109

Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68-74. doi:10.1038/nature15393

Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, N.Y.). 2017;357(6349):409-413. doi:10.1126/science.aan6733

Musacchio L, Caruso G, Pisano C, et al. PARP inhibitors in endometrial cancer: current status and perspectives. Cancer Manag Res. 2020;12:6123-6135. doi:10.2147/cmar.S221001

Green AK, Tabatabai SM, Aghajanian C, et al. Clinical trial participation among older adult medicare fee-for-service beneficiaries with cancer. JAMA Oncol. 2022;8(12):1786-1792. doi:10.1001/jamaoncol.2022.5020

Williams CD, Bullard AJ, O'Leary M, Thomas R, Tst R, Goldstein K. Racial/ethnic disparities in BRCA counseling and testing: a narrative review. J Racial Ethn Health Disparities. 2019;6(3):570-583. doi:10.1007/s40615-018-00556-7

Doll KM, Khor S, Odem-Davis K, et al. Role of bleeding recognition and evaluation in Black-White disparities in endometrial cancer. Am J Obstet Gynecol. 2018;219(6):593.e1-593.e14. doi:10.1016/j.ajog.2018.09.040

Doll KM, Romano SS, Marsh EE, Robinson WR. Estimated performance of transvaginal ultrasonography for evaluation of postmenopausal bleeding in a simulated cohort of Black and White women in the US. JAMA Oncol. 2021;7(8):1158-1165. doi:10.1001/jamaoncol.2021.1700

Santiago-Rodríguez EJ, Shariff-Marco S, Gomez SL, Hiatt RA. Disparities in colorectal cancer screening by time in the U.S. and race/ethnicity, 2010-2018. Am J Prev Med. 2023;65(1):74-82. doi:10.1016/j.amepre.2023.01.033

Borrell LN, Elhawary JR, Fuentes-Afflick E, et al. Race and genetic ancestry in medicine - a time for reckoning with racism. N Engl J Med. 2021;384(5):474-480. doi:10.1056/NEJMms2029562

Chapman-Davis E, Webster EM, Balogun OD, Frey MK, Holcomb K. Landmark series on disparities: uterine cancer and strategies for mitigation. Ann Surg Oncol. 2023;30(1):48-57. doi:10.1245/s10434-022-12765-w